AU2002314102A1 - Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways - Google Patents
Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airwaysInfo
- Publication number
- AU2002314102A1 AU2002314102A1 AU2002314102A AU2002314102A AU2002314102A1 AU 2002314102 A1 AU2002314102 A1 AU 2002314102A1 AU 2002314102 A AU2002314102 A AU 2002314102A AU 2002314102 A AU2002314102 A AU 2002314102A AU 2002314102 A1 AU2002314102 A1 AU 2002314102A1
- Authority
- AU
- Australia
- Prior art keywords
- combination
- tiotropium
- obstructive airways
- inhalation
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000414 obstructive effect Effects 0.000 title abstract 3
- 229940110309 tiotropium Drugs 0.000 title abstract 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 title abstract 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 2
- 239000000812 cholinergic antagonist Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229940112141 dry powder inhaler Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 229940071648 metered dose inhaler Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 229960000257 tiotropium bromide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29355501P | 2001-05-25 | 2001-05-25 | |
| US60/293,555 | 2001-05-25 | ||
| US30384501P | 2001-07-09 | 2001-07-09 | |
| US60/303,845 | 2001-07-09 | ||
| PCT/EP2002/005643 WO2002096423A2 (en) | 2001-05-25 | 2002-05-23 | Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002314102A1 true AU2002314102A1 (en) | 2002-12-09 |
Family
ID=26968011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002314102A Abandoned AU2002314102A1 (en) | 2001-05-25 | 2002-05-23 | Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1397135B1 (enExample) |
| JP (1) | JP2004530705A (enExample) |
| AT (1) | ATE347361T1 (enExample) |
| AU (1) | AU2002314102A1 (enExample) |
| CA (1) | CA2448363A1 (enExample) |
| DE (1) | DE60216588T2 (enExample) |
| ES (1) | ES2276942T3 (enExample) |
| MX (1) | MXPA03010791A (enExample) |
| WO (1) | WO2002096423A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| ATE384529T1 (de) * | 2003-03-28 | 2008-02-15 | Nycomed Gmbh | Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen |
| BRPI0409492A (pt) * | 2003-04-18 | 2006-05-02 | Pharmacia & Up John Company Ll | terapias de combinação |
| WO2004103407A2 (en) * | 2003-05-22 | 2004-12-02 | Altana Pharma Ag | Composition comprising a pde4 inhibitor and a pde5 inhibitor |
| EP1651222A1 (en) * | 2003-07-29 | 2006-05-03 | Boehringer Ingelheim International Gmbh | Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders |
| EP1504756A1 (en) * | 2003-08-06 | 2005-02-09 | Kyowa Hakko Kogyo Co., Ltd | Medicament compositions comprising a heterocyclic compound and an anticholinergic |
| PL1713471T3 (pl) * | 2004-02-06 | 2012-06-29 | Meda Pharma Gmbh & Co Kg | Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych |
| RU2006132043A (ru) * | 2004-02-06 | 2008-03-20 | МЕДА Фарма ГмбХ унд Ко.КГ (DE) | Комбинация и фармацевтический препарат для лечения ринита |
| AU2005210085B2 (en) | 2004-02-06 | 2010-06-24 | Meda Pharma Gmbh & Co. Kg | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD |
| US7507745B2 (en) | 2004-02-20 | 2009-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins |
| JP2007523117A (ja) * | 2004-02-20 | 2007-08-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗コリン作用薬及びｐｅｇｓｕｎｅｒｃｅｐｔを基にした新規な医薬組成物 |
| NZ551669A (en) * | 2004-05-31 | 2010-07-30 | Almirall Lab | Combinations comprising antimuscarinic agents and PDE4 inhibitors |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| US20060079544A1 (en) * | 2004-08-13 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic |
| MX2007011273A (es) | 2005-03-16 | 2007-11-08 | Meda Pharma Gmbh & Co Kg | La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias. |
| US8012971B2 (en) * | 2005-04-28 | 2011-09-06 | Dainippon Sumitomo Pharma Co., Ltd. | Therapeutic agent for chronic obstructive pulmonary disease |
| DE102005035112A1 (de) * | 2005-07-27 | 2007-02-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Verfahren zur Herstellung von Tiotropiumsalzen unter Anwendung von in organischen Lösungsmitteln löslichen N-Methylscopiniumsalzen |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| WO2007071313A2 (en) | 2005-12-21 | 2007-06-28 | Meda Pharma Gmbh & Co Kg | Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| EP1905440A1 (de) * | 2006-09-06 | 2008-04-02 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EA021019B1 (ru) | 2009-06-18 | 2015-03-31 | Концерт Фармасьютикалс, Инк. | Дейтерированные производные изоиндолин-1,3-диона |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69525978T2 (de) * | 1995-06-06 | 2002-12-19 | Pfizer | Trizyclische 5,6-dihydro-9h-pyrazolo(3,4-c)-1,2,4-triazolo(4,3-alpha)pyridine |
| DE10110772A1 (de) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
-
2002
- 2002-05-23 ES ES02740638T patent/ES2276942T3/es not_active Expired - Lifetime
- 2002-05-23 EP EP02740638A patent/EP1397135B1/en not_active Expired - Lifetime
- 2002-05-23 AT AT02740638T patent/ATE347361T1/de active
- 2002-05-23 JP JP2002592933A patent/JP2004530705A/ja active Pending
- 2002-05-23 AU AU2002314102A patent/AU2002314102A1/en not_active Abandoned
- 2002-05-23 WO PCT/EP2002/005643 patent/WO2002096423A2/en not_active Ceased
- 2002-05-23 CA CA002448363A patent/CA2448363A1/en not_active Abandoned
- 2002-05-23 DE DE60216588T patent/DE60216588T2/de not_active Expired - Lifetime
- 2002-05-23 MX MXPA03010791A patent/MXPA03010791A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03010791A (es) | 2004-03-02 |
| DE60216588T2 (de) | 2007-09-20 |
| WO2002096423A3 (en) | 2003-02-06 |
| ATE347361T1 (de) | 2006-12-15 |
| CA2448363A1 (en) | 2002-12-05 |
| WO2002096423A2 (en) | 2002-12-05 |
| DE60216588D1 (de) | 2007-01-18 |
| ES2276942T3 (es) | 2007-07-01 |
| EP1397135A2 (en) | 2004-03-17 |
| JP2004530705A (ja) | 2004-10-07 |
| EP1397135B1 (en) | 2006-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03010791A (es) | Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias. | |
| WO2002094273A3 (en) | Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways | |
| WO2002096422A3 (en) | Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways | |
| NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| NZ585857A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| WO2002078675A3 (en) | Particles for inhalation having sustained release properties | |
| JP2016040316A5 (enExample) | ||
| CA2474479A1 (en) | Composition for inhalation | |
| SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
| NZ606548A (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| UA82217C2 (uk) | Медикамент, що містить бета2-агоніст у комбінації з будезонідом, для лікування запальних або обструктивних хвороб дихальних шляхів | |
| NZ593695A (en) | Alkaloid aminoester derivatives and medicinal composition thereof | |
| WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| MXPA05009629A (es) | Composiciones que contienen trospio. | |
| TN2009000504A1 (en) | Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray | |
| KR20070042917A (ko) | 소아 천식의 치료 | |
| WO2004012653A3 (en) | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof | |
| TW200602054A (en) | Use of compounds in a dry powder inhaler | |
| NO20051463L (no) | Inhaleringssammensetninger med hoy legemiddelandel | |
| AU2003292120B2 (en) | New synergistic combination comprising roflumilast and formoterol | |
| AU2003288169B8 (en) | Synergistic combination comprising roflumilast and (R,R) -formoterol | |
| PL365736A1 (en) | Bimodal dry powder formulation for inhalation | |
| HK1081862B (en) | Synergistic combination comprising roflumilast and (r,r)-formoterol | |
| GEAP202516740A (en) | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |